BRIEF published on 09/13/2025 at 01:05, 9 months 8 days ago BioNxt Settles Debt with Share and Cash Agreement Debt Settlement Canadian Securities Exchange Regulatory Approvals BioNxt Solutions Share Agreement
BRIEF published on 09/13/2025 at 01:05, 9 months 8 days ago BioNxt règle sa dette grâce à un accord en actions et en espèces Bourse Des Valeurs Canadiennes Approbations Réglementaires Règlement De La Dette Solutions BioNxt Accord De Partage
PRESS RELEASE published on 09/13/2025 at 01:00, 9 months 8 days ago BioNxt Announces Shares for Debt Settlement BioNxt Solutions Inc. announces a debt settlement agreement with a creditor, issuing common shares and making a cash payment. Company focuses on bioscience innovations and drug delivery technologies Innovation Debt Settlement BioScience Drug Delivery BioNxt
BRIEF published on 09/05/2025 at 09:10, 9 months 16 days ago BioNxt Solutions fait ses débuts sur le marché OTCQB Divulgation Financière Marché OTCQB Développement De Médicaments Investisseurs Américains Solutions BioNxt
BRIEF published on 09/05/2025 at 09:10, 9 months 16 days ago BioNxt Solutions Debuts on OTCQB Market Financial Disclosure Drug Development US Investors BioNxt Solutions OTCQB Market
PRESS RELEASE published on 09/05/2025 at 09:05, 9 months 16 days ago BioNxt Solutions Completes Up-Listing to The OTCQB Market BioNxt Solutions Inc. announces up-listing to OTCQB market, expanding access to US investors. Three drug development programs underway in Europe & North America. Company focuses on innovative drug delivery platforms Drug Development BioNxt Solutions Inc. US Investors OTCQB Market Innovative Drug Delivery
BRIEF published on 09/02/2025 at 09:10, 9 months 19 days ago BioNxt Begins Lab-Scale Development of Semaglutide Oral Film Drug Delivery BioNxt Solutions Semaglutide ODF Lab-scale Formulation Patent Development
BRIEF published on 09/02/2025 at 09:10, 9 months 19 days ago BioNxt commence le développement à l'échelle du laboratoire d'un film oral à base de sémaglutide Solutions BioNxt Administration De Médicaments Semaglutide ODF Formulation À L'échelle Du Laboratoire Développement De Brevets
PRESS RELEASE published on 09/02/2025 at 09:05, 9 months 19 days ago Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt BioNxt Solutions announces receipt of Semaglutide API for laboratory-scale testing of ODF delivery system. Collaboration with Gen Plus for European drug development hub BioNxt Solutions Semaglutide API ODF Delivery System Laboratory-scale Testing Gen Plus
BRIEF published on 08/23/2025 at 02:10, 9 months 29 days ago BioNxt Solutions Engages in Investor Relations Initiatives Brand Visibility Investor Relations BioNxt Solutions Apaton Finance Cayo Ventures
Published on 06/20/2026 at 01:00, 1 day 13 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 14 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 9 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 12 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 13 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 16 hours 46 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 8 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 17 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 17 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 19 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 18 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 18 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 18 hours ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 18 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
